- Home
- SLNO vs VKTX Comparison
SLNO vs VKTX Comparison
Compare SLNO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- VKTX
- Stock Information
- Founded
- SLNO 1999
- VKTX 2012
- Country
- SLNO United States
- VKTX United States
- Employees
- SLNO N/A
- VKTX N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SLNO Health Care
- VKTX Health Care
- Exchange
- SLNO Nasdaq
- VKTX Nasdaq
- Market Cap
- SLNO 3.2B
- VKTX 2.8B
- IPO Year
- SLNO 2014
- VKTX 2015
- Fundamental
- Price
- SLNO $73.35
- VKTX $27.14
- Analyst Decision
- SLNO Strong Buy
- VKTX Buy
- Analyst Count
- SLNO 9
- VKTX 12
- Target Price
- SLNO $103.33
- VKTX $84.00
- AVG Volume (30 Days)
- SLNO 744.8K
- VKTX 2.9M
- Earning Date
- SLNO 05-07-2025
- VKTX 07-23-2025
- Dividend Yield
- SLNO N/A
- VKTX N/A
- EPS Growth
- SLNO N/A
- VKTX N/A
- EPS
- SLNO N/A
- VKTX N/A
- Revenue
- SLNO N/A
- VKTX N/A
- Revenue This Year
- SLNO N/A
- VKTX N/A
- Revenue Next Year
- SLNO N/A
- VKTX N/A
- P/E Ratio
- SLNO N/A
- VKTX N/A
- Revenue Growth
- SLNO N/A
- VKTX N/A
- 52 Week Low
- SLNO $36.93
- VKTX $18.92
- 52 Week High
- SLNO $80.99
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- SLNO 49.78
- VKTX 48.69
- Support Level
- SLNO $72.29
- VKTX $26.66
- Resistance Level
- SLNO $78.32
- VKTX $28.33
- Average True Range (ATR)
- SLNO 2.74
- VKTX 1.34
- MACD
- SLNO -0.57
- VKTX -0.12
- Stochastic Oscillator
- SLNO 27.11
- VKTX 32.21
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.